Skip to content
  • Home
  • Journalists
    • Headlines
  • Community
    • Businesses
    • Jobs
    • Learning
    • Marketplace
  • Store
(@)

F.D.A. Approves New Treatment for Early Alzheimer’s

The drug, Leqembi, may modestly slow cognitive decline in early stages of the disease but carries some safety risks. Still, data suggests it is more promising than the small number of other available treatments.

Pam Belluck
Author: Pam Belluck

Written by

Pam Belluck

in

Centers for Medicare and Medicaid Services, Drugs (Pharmaceuticals), Eisai Co Ltd, Food and Drug Administration, Labeling and Labels (Product), Medicare, New England Journal of Medicine, Placebos, United States
←Is The ‘In And Out’ Instagram Trend Worth Trying? Here’s What Experts Say
Love Letter: Stranger Than ‘Sweetie’→

More posts

  • Pure Joy: Photographer Laylah Amatullah Barrayn Captures Her First ESSENCE Festival Of Culture

  • Angry crowd confronts Republican Rep. Mike Flood at Nebraska town hall

  • Rhea Seehorn celebrates her ‘Pluribus’ Emmy nomination as she waits to hear about Carol and the atom bomb

  • Emmy Nominations Analysis: ‘The Pitt’ And ‘Hacks’ Dominance Proves It Helps To Be On A Show Voters Actually Watch

About Us


Support Us

Trademark & Copyright 1998 – 2025 · MOSAEC

  • Facebook
  • Instagram
  • LinkedIn
  • YouTube